Bulk Pharmaceutical API Sources for ESCITALOPRAM OXALATE

Bulk Pharmaceutical API Sources for ESCITALOPRAM OXALATE

Vendor	Vendor Homepage	Vendor Sku	API Url
NIH Clinical Collection		SAM001246668
Hangzhou Trylead Chemical Technology		TL8001823
NovoSeek		146571
MolPort		MolPort-003-666-613
Hangzhou APIChem Technology		AC-6770
ABI Chem		AC1L3TGZ

ESCITALOPRAM OXALATE BULK API SOURCING

Last updated: February 19, 2026

This report analyzes the global landscape of bulk active pharmaceutical ingredient (API) suppliers for escitalopram oxalate, focusing on manufacturing capacity, regulatory compliance, and key market players. The analysis is critical for pharmaceutical companies seeking reliable and cost-effective sourcing strategies to meet global demand for escitalopram oxalate, a selective serotonin reuptake inhibitor (SSRI) used to treat depression and generalized anxiety disorder.

What are the primary manufacturing regions for escitalopram oxalate API?

The manufacturing of escitalopram oxalate API is concentrated in specific geographical regions due to established pharmaceutical manufacturing infrastructure, skilled labor, and access to raw materials.

• Asia, particularly India and China, dominates global production. These countries benefit from large-scale chemical synthesis capabilities, competitive labor costs, and robust supply chains for intermediate chemicals.
• Europe, with countries like Germany and Italy, maintains a significant presence, often focusing on higher-value, complex API manufacturing and adherence to stringent quality standards.
• North America, primarily the United States, also has API manufacturing capabilities but often imports a substantial portion of its bulk API requirements for escitalopram oxalate, leveraging cost efficiencies from Asian manufacturers.

Who are the key global manufacturers of escitalopram oxalate API?

Several companies have established significant manufacturing capacities for escitalopram oxalate API. These manufacturers vary in their scale, regulatory approvals, and market reach.

• Indian Manufacturers:

  • Laurus Labs: A significant producer with multiple manufacturing sites and strong regulatory approvals, including US FDA and EDQM certifications. They offer a broad portfolio of APIs, including escitalopram oxalate [1].
  • Divi's Laboratories: Known for its large-scale API production and backward integration, Divi's is a prominent supplier to global markets. Their facilities are subject to regular international regulatory inspections [2].
  • Dr. Reddy's Laboratories: A diversified pharmaceutical company with API manufacturing capabilities, Dr. Reddy's produces and supplies escitalopram oxalate to regulated and semi-regulated markets.
  • Sun Pharmaceutical Industries: As one of India's largest pharmaceutical companies, Sun Pharma has substantial API manufacturing operations, including for key psychiatric medications.

• Chinese Manufacturers:

  • Hengdian World المتحدة Pharma Co., Ltd. (HWP): A major API producer in China with a broad range of therapeutic areas, HWP manufactures and exports escitalopram oxalate.
  • Zhejiang Huahai Pharmaceutical Co., Ltd.: A leading API exporter from China, Huahai has extensive manufacturing capacity and a strong regulatory track record, supplying to major global markets.
  • Anqiu Lu An Pharmaceutical Co., Ltd.: Specializes in the synthesis of various pharmaceutical intermediates and APIs, including escitalopram oxalate.

• European Manufacturers:

  • Aceto Corporation: While a global distributor, Aceto sources and supplies APIs, including escitalopram oxalate, from qualified manufacturing partners, often with European or US regulatory filings.
  • Siegfried AG: A Swiss-based company with manufacturing sites in Europe and the US, Siegfried offers contract manufacturing and custom synthesis, including for APIs like escitalopram oxalate, adhering to high-quality standards.

What are the regulatory requirements for escitalopram oxalate API manufacturing?

Manufacturing escitalopram oxalate API for sale in major pharmaceutical markets necessitates strict adherence to global regulatory standards. These ensure the quality, safety, and efficacy of the API.

• Good Manufacturing Practices (GMP): All manufacturing facilities must comply with GMP guidelines as established by regulatory bodies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). This covers all aspects of production, from raw material control to finished product testing.
• Drug Master Files (DMFs): Manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory authorities to review the API information without disclosing proprietary details to the drug product manufacturer.
  • US DMFs: Filed with the FDA.
  • European CEPs (Certificates of Suitability to the monographs of the European Pharmacopoeia): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), these demonstrate that the API complies with the requirements of the European Pharmacopoeia.
• Site Inspections: Manufacturing sites are subject to routine inspections by regulatory authorities (e.g., FDA, EMA) to verify ongoing GMP compliance.
• Impurity Profiling: Manufacturers must rigorously control and report potential impurities, including genotoxic impurities, in accordance with International Council for Harmonisation (ICH) guidelines (e.g., ICH M7 for genotoxic impurities).
• Quality Control and Assurance: Robust quality control (QC) and quality assurance (QA) systems are essential. This includes validated analytical methods for testing raw materials, in-process samples, and the final API.

What are the critical quality attributes (CQAs) and specifications for escitalopram oxalate API?

Ensuring consistent quality of escitalopram oxalate API is paramount for the safety and efficacy of the final drug product. Key quality attributes and specifications are defined by pharmacopoeias and regulatory filings.

• Assay: The content of escitalopram oxalate must fall within a defined range, typically 98.0% to 102.0% on an anhydrous and solvent-free basis, as per USP or EP monographs [3].
• Related Substances/Impurities:
  • Specified Impurities: Limits are set for known process-related impurities and degradation products. For example, impurities like (S)-citalopram N-oxide or other chiral impurities must be controlled below strict thresholds.
  • Unspecified Impurities: A general limit is set for any single unidentified impurity, often not exceeding 0.10%.
  • Total Impurities: A limit is set for the sum of all impurities, typically not exceeding 0.50% or 1.0%.
  • Chiral Purity: As escitalopram is the (S)-enantiomer of citalopram, the control of the (R)-enantiomer (dextrocitalopram) is critical. Limits are usually very stringent, often below 0.2% or 0.5% [3].
• Water Content: Measured by Karl Fischer titration, typically not exceeding 0.5% or 1.0%.
• Residue on Ignition (Sulphated Ash): A measure of inorganic impurities, typically not exceeding 0.1%.
• Heavy Metals: Limits are defined for heavy metal contamination, usually not exceeding 10 ppm or 20 ppm.
• Residual Solvents: Compliance with ICH Q3C guidelines for residual solvents is mandatory, with specific limits for solvents used in the manufacturing process (e.g., methanol, ethanol, isopropanol, ethyl acetate).
• Particle Size Distribution (PSD): While not always a mandatory pharmacopoeial test, PSD can be a critical parameter for downstream processing (e.g., formulation into tablets). Manufacturers often provide data or control this parameter based on customer requirements.
• Polymorphism: Escitalopram oxalate can exist in different polymorphic forms. Manufacturers need to control and characterize the polymorphic form to ensure consistent dissolution and bioavailability of the final drug product.

What are the supply chain considerations for escitalopram oxalate API?

Sourcing escitalopram oxalate API involves several critical supply chain considerations to ensure continuity, cost-effectiveness, and quality.

• Backward Integration: Manufacturers with strong backward integration into key starting materials and intermediates often offer greater supply chain stability and cost control. This reduces reliance on external suppliers for critical precursors.
• Geopolitical Risks: Dependence on a single region or country for API supply can expose companies to geopolitical risks, trade disputes, and regulatory changes. Diversification of suppliers across different geographical regions is advisable.
• Regulatory Audit Burden: Each potential supplier requires a rigorous quality and regulatory audit. For multi-source strategies, this audit process must be managed efficiently.
• Lead Times and Inventory Management: Understanding the lead times for API production and delivery is crucial for effective inventory management and avoiding stock-outs.
• Intellectual Property (IP): While the primary patents for escitalopram have expired in major markets, process patents or specific polymorphic form patents may still exist. Sourcing strategies must consider IP landscapes to avoid infringement.
• Cost Analysis: A comprehensive cost analysis should include not only the per-kilogram price of the API but also shipping, import duties, audit costs, and the potential cost of supply chain disruptions.
• Quality Agreements: Establishing robust Quality Agreements between the API supplier and the drug product manufacturer is essential. These agreements define roles, responsibilities, and expectations regarding quality control, change management, and regulatory compliance.

How do Indian and Chinese API manufacturers compare in the global escitalopram oxalate market?

Indian and Chinese manufacturers are the dominant players in the global escitalopram oxalate API market, each with distinct strengths and market positioning.

• India:

  • Strengths: Strong regulatory track record with US FDA and EDQM approvals; well-established GMP compliance culture; significant R&D capabilities for process optimization; a robust ecosystem of supporting chemical industries; established relationships with global pharmaceutical companies.
  • Market Focus: Primarily targets regulated markets (US, Europe) due to strong regulatory compliance. Often positioned for higher-value segments.
  • Cost Structure: Competitive, but generally higher than China due to stricter regulatory compliance costs and labor.

• China:

  • Strengths: Massive production capacity; significant cost advantages due to lower labor and environmental compliance costs (historically, though this is evolving); rapid scale-up capabilities; extensive access to chemical raw materials.
  • Market Focus: Historically strong in semi-regulated and emerging markets. Increasingly improving regulatory compliance to enter regulated markets, though with a more varied track record.
  • Cost Structure: Typically offers the lowest API pricing globally.

Comparison Table:

Feature	Indian Manufacturers	Chinese Manufacturers
Regulatory Compliance	Strong (US FDA, EDQM focus)	Improving, historically variable
Production Scale	Large to very large	Very large to massive
Cost Competitiveness	High	Very High
R&D/Process Innovation	Significant	Growing
Supply Chain Stability	Generally high due to established processes	Can be subject to policy changes and disruptions
Market Reach	Global, with strong presence in regulated markets	Global, significant in emerging markets, growing in regulated
Quality Systems	Robust and mature	Developing, improving significantly

What is the market outlook for escitalopram oxalate API?

The market for escitalopram oxalate API is mature but stable, driven by the consistent demand for antidepressants and anxiolytics.

• Steady Demand: Escitalopram remains a first-line treatment option for depression and anxiety disorders. The global prevalence of these conditions ensures a continuous demand for the API.
• Generic Competition: With patent expiries, the market is heavily characterized by generic competition. This drives a constant focus on cost efficiency in API manufacturing and sourcing.
• Emerging Markets: Growth in emerging markets, where access to mental health treatments is expanding, presents an opportunity for API suppliers.
• Consolidation and Partnerships: The API sector may see continued consolidation as larger players acquire smaller ones to expand capacity or market share. Strategic partnerships between API manufacturers and generic drug formulators are also likely.
• Regulatory Evolution: Increasing scrutiny on API quality and supply chain transparency, particularly concerning impurities like nitrosamines, will continue to shape manufacturing practices and supplier selection. Manufacturers who proactively invest in advanced analytical capabilities and robust quality systems will be better positioned.

Key Takeaways

• India and China are the dominant global sources for bulk escitalopram oxalate API, offering scale and cost competitiveness.
• Regulatory compliance (GMP, DMFs, impurity control) is paramount for market access, particularly in regulated markets like the US and Europe.
• Indian manufacturers generally have a stronger regulatory standing in Western markets, while Chinese manufacturers offer significant cost advantages.
• Key quality attributes include assay, stringent control of related substances and chiral impurities, water content, and residual solvents.
• Supply chain diversification, robust quality agreements, and a thorough understanding of geopolitical and IP landscapes are critical for securing reliable API supply.
• The market outlook is stable, driven by consistent demand, with growth opportunities in emerging markets and continued emphasis on cost efficiency and quality assurance.

FAQs

1. What is the typical lead time for procuring bulk escitalopram oxalate API from major manufacturers? Lead times can vary significantly but typically range from 4 to 12 weeks for established orders, depending on the manufacturer's production schedule, order volume, and existing inventory. Urgent or custom orders may incur longer lead times or premium pricing.

2. Are there any significant emerging API manufacturers for escitalopram oxalate outside of India and China? While India and China dominate production volume, some European and North American companies offer specialized manufacturing services or niche production, often focusing on very high-purity or custom synthesis requirements, though at a higher cost. They typically do not compete on bulk volume for the general market.

3. What are the primary challenges in ensuring the chiral purity of escitalopram oxalate API? The primary challenge is the synthetic route's efficiency in isolating the (S)-enantiomer and preventing racemization. This requires precise control of reaction conditions and effective chiral separation techniques. Rigorous analytical testing using chiral chromatography is essential to detect and quantify the unwanted (R)-enantiomer.

4. How do recent global supply chain disruptions (e.g., pandemics, shipping crises) impact the sourcing of escitalopram oxalate API? Disruptions can lead to increased lead times, higher shipping costs, and potential raw material shortages for API precursors. Companies have responded by increasing safety stocks, diversifying supplier bases, and exploring near-shoring or regional sourcing options where feasible, though cost remains a significant factor favoring Asian production.

5. What is the typical shelf life of escitalopram oxalate API, and how is it determined? The typical shelf life for stable escitalopram oxalate API is generally 2 to 5 years when stored under recommended conditions (e.g., protected from light and moisture, at controlled room temperature). Shelf life is determined through long-term stability studies conducted according to ICH Q1A(R2) guidelines, which involve testing the API at specified intervals under various temperature and humidity conditions to assess degradation.

---

Citations

[1] Laurus Labs. (n.d.). API Portfolio. Retrieved from [Manufacturer's Website - Specific page for APIs or Escitalopram Oxalate if available, otherwise general API page] (Note: Direct URL to a specific product page is ideal but may not be publicly accessible for proprietary details).

[2] Divi's Laboratories. (n.d.). API Manufacturing. Retrieved from [Manufacturer's Website - General API manufacturing overview] (Note: Similar to [1], direct product page reference may be proprietary).

[3] United States Pharmacopeia. (2023). USP 46, Monograph 3700: Escitalopram Oxalate. Retrieved from [USP Website or relevant database access] (Requires subscription/access). (Note: European Pharmacopoeia (EP) monograph would also be relevant here if cited.)